FBIO Long Call Strategy

FBIO (Fortress Biotech, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; ConVax; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies.

FBIO (Fortress Biotech, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $71.8M, a trailing P/E of 9.13, a beta of 1.16 versus the broader market, a 52-week range of 1.66-4.53, average daily share volume of 683K, a public-listing history dating back to 2011, approximately 101 full-time employees. These structural characteristics shape how FBIO stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 1.16 places FBIO roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline. The trailing P/E of 9.13 is on the value side, where IV often compresses outside event windows because forward growth expectations are already discounted into the share price.

What is a long call on FBIO?

A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.

Current FBIO snapshot

As of May 15, 2026, spot at $2.40, ATM IV 251.60%, IV rank 47.70%, expected move 72.13%. The long call on FBIO below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.

Why this long call structure on FBIO specifically: FBIO IV at 251.60% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 72.13% (roughly $1.73 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated FBIO expiries trade a higher absolute premium for lower per-day decay. Position sizing on FBIO should anchor to the underlying notional of $2.40 per share and to the trader's directional view on FBIO stock.

FBIO long call setup

The FBIO long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With FBIO near $2.40, the first option leg uses a $2.40 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed FBIO chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 FBIO shares for the stock leg in covered calls and collars).

ActionTypeStrike / BasisPremium (est)
Buy 1Call$2.40N/A

FBIO long call risk and reward

Net Premium / Debit
N/A
Max Profit (per contract)
Unbounded
Max Loss (per contract)
Unbounded
Breakeven(s)
None on modeled curve
Risk / Reward Ratio
N/A

Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.

FBIO long call payoff curve

Modeled P&L at expiration across a range of underlying prices for the long call on FBIO. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use long call on FBIO

Long calls on FBIO express a bullish thesis with defined risk; traders use them ahead of FBIO catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.

FBIO thesis for this long call

The market-implied 1-standard-deviation range for FBIO extends from approximately $0.67 on the downside to $4.13 on the upside. A FBIO long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current FBIO IV rank near 47.70% is mid-range against its 1-year distribution, so the IV signal is neutral; the long call thesis on FBIO should anchor more to the directional view and the expected-move geometry. As a Healthcare name, FBIO options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to FBIO-specific events.

FBIO long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. FBIO positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move FBIO alongside the broader basket even when FBIO-specific fundamentals are unchanged. Long-premium structures like a long call on FBIO are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current FBIO chain quotes before placing a trade.

Frequently asked questions

What is a long call on FBIO?
A long call on FBIO is the long call strategy applied to FBIO (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With FBIO stock trading near $2.40, the strikes shown on this page are snapped to the nearest listed FBIO chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are FBIO long call max profit and max loss calculated?
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the FBIO long call priced from the end-of-day chain at a 30-day expiry (ATM IV 251.60%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a FBIO long call?
The breakeven for the FBIO long call priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current FBIO market-implied 1-standard-deviation expected move is approximately 72.13%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a long call on FBIO?
Long calls on FBIO express a bullish thesis with defined risk; traders use them ahead of FBIO catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
How does current FBIO implied volatility affect this long call?
FBIO ATM IV is at 251.60% with IV rank near 47.70%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.

Related FBIO analysis